Three Rivers acquires hepatitis C drug from Valeant
Infergen, or consensus interferon, is a bio-optimized, selective and highly potent type 1 interferon alpha. It is currently indicated as monotherapy for the treatment of adult patients suffering
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.